NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward
Globe Newswire•21/10/2026•09:35 ET
0
Key Highlights
- ➤Abu Dhabi MoU covers CNS research, training, clinical development and real-world evidence exchange
- ➤Two Abu Dhabi children receive investigational NEO100 through NeOnc’s Compassionate Care program
- ➤NeOnc expects a third child from India to enter NEO100 compassionate care this week
- ➤Phase 2a NEO100 study met its primary endpoint with 48.9% six-month progression-free survival
- ➤NEO100 trial’s 48.9% six-month progression-free survival exceeded the 20% benchmark
Expert Statements
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings
“For families facing brain cancer, access to investigational treatments and clinical research opportunities matters deeply,”
DENVER, Oct. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — “I wish someone had told me about that company.”
That is a familiar reaction when a stock attracts attention after investors have spent months overlooking it. The harder task is recognizing a developing business story while the chart still gives the market reasons to look away.
Get started
Create a free account to read the full story.